This crossover, subject-blinded, clinical trial (n=0, withdrawn) aimed to correlate changes in brain activity with the reduction in suicidal ideation (SI) in response to a single intramuscular dose of ketamine.
A randomised, double-blind, crossover pilot study planned to test whether specific EEG changes correlate with reduction in suicidal ideation following a single IM ketamine dose (0.5 mg/kg) compared with placebo in inpatients with clinically significant SI.
Primary aims were to identify EEG biomarkers associated with anti-suicidal response and to assess the acute effectiveness of IM ketamine on suicidal ideation; outcomes included EEG measures and standard clinical scales (MADRS item 10, C-SSRS).
Participants receive IM ketamine on day 1 then IM placebo on day 2 (crossover).
Racemic ketamine (Ketalar) 0.5 mg/kg IM, single-session; crossover with next-day placebo.
Matching IM saline placebo administered on day 2.
Participants receive IM placebo on day 1 then IM ketamine on day 2 (crossover).
Matching IM saline placebo administered on day 1.
Racemic ketamine (Ketalar) 0.5 mg/kg IM on day 2.